Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Nebraska Millennium Pharmaceuticals, Inc. |
---|---|
Information provided by: | University of Nebraska |
ClinicalTrials.gov Identifier: | NCT00571493 |
This is a Phase I/II trial designed to study the toxicity and Maximum Tolerated Dose of VELCADE in combination with BEAM and autologous hematopoietic stem cell transplantation and to obtain a preliminary estimate of the response rate to this combination.
Condition | Intervention | Phase |
---|---|---|
Non-Hodgkin's Lymphoma Mantle Cell Lymphoma |
Drug: Bortezomib Drug: BEAM Procedure: autologous peripheral blood stem cell transplantation |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase I/II Study of VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Indolent Non-Hodgkin's Lymphoma, Transformed or Mantle Cell Lymphoma |
Estimated Enrollment: | 44 |
Study Start Date: | April 2006 |
Estimated Study Completion Date: | December 2009 |
Arms | Assigned Interventions |
---|---|
Dose cohort 1 - 4: Experimental
3 patients will be accrued in each dose cohort. Enrollment will start at Dose Cohort #1. If 0-1 patients experience a dose-limiting toxicity, the next dose cohort will be initiated. Escalation to a higher dose cohort will not commence before 2 patients have achieved engraftment on that dose cohort to evaluate for toxicities. If 2 of 3 patients in Dose Cohort #1-4 have a dose-limiting toxicity, 3 additional patients will be added to that dose level. If 3 of these 6 patients experience a dose limiting toxicity defined as grade > 2 on the Bearman scale, DLT will be reached. No further dose escalation will take place. |
Drug: Bortezomib
Velcade will be administered in four dose cohorts, 0.8 mg/m², 1.0mg/m², 1.3mg/m² and 1.5mg/m². Three patients will be accrued in each dose cohort with enrollment starting at dose cohort 1, 0.8mg/m². Subjects participating in this study will receive Velcade on Days -11, -8, -5, and -2.
Drug: BEAM
carmustine 300mg/m2, etoposide 100mg/m2 BID, cytarabine 100mg/m2 BID, melphalan 140mg/m2 BID
Procedure: autologous peripheral blood stem cell transplantation
Peripheral blood stem cells will be collected as per the discretion of the treating physician. Once an adequate number of CD34+ cells/kg have been collected (as per existing institutional guidelines) the patient will begin the preparative regimen with for transplant. On day 0 of treatment, the previously stored hematopoietic stem cells will be re-infused. The cells will be removed from the storage freezer, brought to the patient area, thawed in a 370C water bath, and administered intravenously through a central line to the patient. Patients will then be cared for as standard transplant patients.
|
Primary Objective: To evaluate in a phase I study the toxicity and MTD of the addition of VELCADE™ (bortezomib) to a standard BEAM autologous transplant regimen. The phase II portion of the study will determine a preliminary estimate of the response rate.
Secondary Objectives: To obtain a preliminary estimate of the response rate to this regimen. To obtain preliminary estimates of event-free and overall survival using this regimen.
Enrolled subjects will receive Velcade in combination with BEAM and Autologous Hematopoietic Stem Cell Transplantation (AHSCT). Phase I treatment will administer Velcade in four dose cohorts,in addition to the BEAM and AHSCT. Three patients will be accrued in each dose cohort with enrollment starting at dose cohort. These subjects will be evaluated to establish the maximum tolerated dose of Velcade in combination with BEAM autologous peripheral blood stem cell transplantation. Once established, the maximum tolerated dose will be utilized in treating an additional 20 subjects.
Follow-Up: Data collected will be utilized to obtain a preliminary estimate of the response rate, event-free and overall survival using this regimen.
Ages Eligible for Study: | 19 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Susan Allen, RN | 402-559-8155 | msallen@unmc.edu |
United States, Nebraska | |
University of Nebraska Medical Center, Section of Oncology/Hematology | Recruiting |
Omaha, Nebraska, United States, 68198-7680 | |
Principal Investigator: Julie M Vose, M.D. |
Study Chair: | Julie M Vose, M.D. | University of Nebraska |
Responsible Party: | University of Nebraska Medical Center ( Julie M. Vose, M.D. Pricipal Investigator ) |
Study ID Numbers: | UNMC-43805, IRB 438-05, Protocol# X05184 |
Study First Received: | December 11, 2007 |
Last Updated: | December 11, 2007 |
ClinicalTrials.gov Identifier: | NCT00571493 |
Health Authority: | United States: Institutional Review Board |
non-hodgkin's lymphoma mantle cell lymphoma BEAM Velcade |
Melphalan Immunoproliferative Disorders Lymphoma, Mantle-Cell Carmustine Bortezomib Lymphoma, small cleaved-cell, diffuse Mantle cell lymphoma |
Etoposide phosphate Lymphatic Diseases Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Lymphoma Etoposide Cytarabine |
Neoplasms Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Immune System Diseases Antineoplastic Agents |
Therapeutic Uses Enzyme Inhibitors Pharmacologic Actions Protease Inhibitors |